Celltrion
South Korea's leading biosimilar manufacturer challenging global pharma giants
Key Changes (30d)
Celltrion Commences Full-Scale CMO Production at U.S. Facility
Celltrion commences full-scale CMO production of Eli Lilly products at its U.S. Branchburg facility, initiating validation for its own manufacturing to create an integrated U.S. supply system.
Source Language Distribution
Language distribution will appear as more signals are collected from diverse sources.
Strategic themes and signal pattern
Strategic Themes
Recent Signal Pattern
Industry Peer Comparison
Why this company matters
Celltrion has proven that Asian companies can compete with global pharma giants in complex biologic drug development, opening new markets for affordable biologics.
- Key domain relevance: Biosimilars, Monoclonal Antibodies, Autoimmune Therapies
- Active monitoring with 1 signals in the last 30 days across 6 tracked sources.
Channel Context
Celltrion is a key company within the Healthtech & Biotech channel. Its official updates regularly contribute to how users track developments in this space.
View channelMarket Context
This company operates in one of SigFact's strongest advantage markets, where official updates often surface first in local language.
See recent signals in this marketPeers and related companies
All companiesAstellas Pharma
Adv. marketMajor Japanese pharma company focused on urology, oncology, and transplantation
AstraZeneca
Anglo-Swedish pharma company with strong oncology and rare disease pipeline
BeiGene
Adv. marketChina's largest global biotech company focused on innovative oncology medicines
Biocon
India's largest biopharmaceutical company and global biosimilars leader
Biofourmis
Digital therapeutics and remote patient monitoring platform
CSL Limited
Global biotech leader in plasma-derived therapies and vaccines
Continue monitoring Celltrion
Follow this company, add it to your watchlist, or explore its signal stream to stay informed.